Keenova Therapeutics Presented XIAFLEX Data
The company showcased new research on Peyronie's disease treatment and a screening tool for sexual health.
Updated on Oct. 8, 2026 in Men’s Health
Live Poll
Do you trust pharmaceutical companies to provide accurate tools for discussing your personal health concerns?
Keenova Therapeutics presented three research presentations at the Sexual Medicine Society of North America annual meeting. The studies focused on the use of XIAFLEX for Peyronie's disease and introduced a new sexual health screening tool.
Why it matters
The findings aim to support clinicians in identifying and treating Peyronie's disease, a condition involving fibrous scar tissue that affects penile curvature. The new screening tool is designed to improve the efficiency of patient assessments in clinical settings.
Clinical trials reported a 65.5% incidence of penile hematoma and a 14.5% rate of penile ecchymosis among participants. The study also noted that localized pruritus occurred in 4% of trial patients.
The players
Keenova Therapeutics
This Dublin-based pharmaceutical company specializes in developing treatments for men's health conditions.
Sexual Medicine Society of North America
This professional medical organization promotes the development and advancement of sexual medicine through research and clinical education.
The details
The presentations detailed the use of XIAFLEX, which is administered via injection into the Peyronie's plaque to treat curvature. The company also unveiled the Men's Sexual Health Screener, developed to help healthcare providers facilitate more efficient discussions regarding sexual health.
Timeline
The Sexual Medicine Society of North America annual meeting was held from October 8-11, 2026.
The Big Picture
The presentation of new pharmaceutical data at the Sexual Medicine Society of North America annual meeting follows a pattern of clinical information exchange common in specialty medicine. This event serves as a primary venue for introducing diagnostic tools and treatment updates to practitioners.
Patients dealing with the symptoms of Peyronie's disease may see more streamlined assessments from their providers due to the new screening tool. The expanded clinical data may also assist doctors in better managing expectations regarding potential treatment side effects like hematoma.
The takeaway
Peyronie's disease remains a significant health concern affecting approximately 1 in 10 men, requiring specialized medical intervention for curvature. Patients are encouraged to discuss sexual health concerns openly with their providers to utilize available screening and treatment options.
Further reading
For more information on clinical approaches to men's health, visit the Men’s Health section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical companies to provide accurate tools for discussing your personal health concerns?
